INCYTE CORP

Incyte’s latest clinical data show Tafasitamab and Zilurgisertib could hit $300M+ revenue by 2028, driving strong M&A interest and reshaping oncology and rare‑disease markets.

Incyte’s new Phase‑II/III data shows INCA033989 and tafasitamab + lenalidomide + R‑CHOP significantly improve outcomes for myelofibrosis, ET and high‑risk B‑cell lymphoma, offering promising efficacy, safety, and competitive pricing for payers and p…

Incyte’s Phase III frontMIND data show tafasitamab + lenalidomide boosts PFS in high‑risk DLBCL, driving a 12% revenue CAGR, strong margins, and new value‑based reimbursement opportunities.

IncYTE’s June 9, 2026 8‑K reveals new board, EY audit, and insider sales, highlighting stronger governance and investor confidence amid tech‑sector growth.

Innovent’s IBI363 shows 100% disease‑control in PD‑L1‑negative NSCLC, while Incyte’s tafasitamab gains Phase III approval momentum—new multi‑modal immunotherapies reshape oncology markets.

Incyte’s frontMIND trial shows tafasitamab + lenalidomide improves PFS in high‑risk DLBCL/HGBL, offering a compelling, potentially high‑margin therapy amid rising oncology competition.

Incyte officer’s new share purchase signals governance shift—boosts shareholder alignment, may accelerate oncology pipeline but raises regulatory and risk concerns.

Incyte’s May 19, 2026 Rule 144 filing shows a senior director selling 15,000 shares at market price—illustrating insider confidence, liquidity, and standard governance in the biopharma sector.

Incyte’s FDA approval of Jakafi XR—once‑daily ruxolitinib for MPNs and GvHD—offers same efficacy with better adherence, while Australia’s axatilimab expands chronic GvHD options.

Incyte’s FDA approval of Jakafi XR—an extended‑release, once‑daily ruxolitinib—could boost MPN and GVHD sales, improve adherence, lower costs, and drive higher‑value reimbursement contracts.